Pharming to divest DNage, focus on Rhucin

Dutch biotech company Pharming Group is planning to divest its wholly owned subsidiary DNage and focus on the commercialization of its lead product, Rhucin, a replacement therapy for patients who suffer from hereditary angioedema, and the development of other biologicals. As a first step of this process, the company has reached an agreement with the former shareholders of DNage, which Pharming acquired in 2006. Pharming initially will keep a majority interest in the share capital of DNage,...